Market Snapshot

BSE Sensex: 81118.6 -0.70%
BSE 500: 35946.69 -0.57%
BSE 200: 11252.01 -0.61%
BSE 100: 25940.81 -0.65%
BSE MidCap: 45681.28 -0.32%
BSE SmallCap: 53370.29 -0.30%
BSE BANKEX: 62570.44 -1.01%
BSE IT: 37839.04 -0.09%
Nifty 50: 24718.6 -0.68%
Nifty 500: 22906.2 -0.61%
Nifty 200: 13825.4 -0.65%
Nifty 100: 25331.35 -0.71%
Nifty Midcap 100: 58227.45 -0.37%
Nifty Small 100: 18374.8 -0.49%
Nifty IT: 38469.25 0.02%
Nifty PSU Bank: 6934.85 -1.18%

News:

Lemon Tree Hotels signs new pr...
Adani Enterprises arm incorpor...
Syngenes Bengaluru-based facil...
NATCO Pharmas Hyderabad-based ...
Arkade Developers acquires 6.2...

Alivus Life Sciences Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

Invest

13 Jun 2025 | 04:14 PM

1,014.20

-14.60 (-1.42%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Outperforms Index

18.19%

Return (1Y)

Beaten Nifty 500 by 14.42%
More Volatile

2.91%

Standard Deviation (1Y)

Higher than Nifty 500 by 1.97%
Not so consistent

6/12

Months

underperformed Nifty 500
AxisDirect View

No View

52 Week High-Low

1,335

819

News & Announcements

Alivus Life Sciences to hold board meeting
37 days ago

Alivus Life Sciences to hold board meeting

09 - May - 2025 12:00 | 37 days ago

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 15 May 2025.
Powered by Capital Market - Live News
Alivus Life Sciences allots 92,096 equity shares under ESOS
46 days ago

Alivus Life Sciences allots 92,096 equity shares under ESOS

30 - Apr - 2025 12:00 | 46 days ago

Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Consequent to the allotment, the paid up equity share capital has increased to 12,26,29,148 equity shares of Rs. 2 each aggregating to Rs. 24,52,58,296/-.
Powered by Capital Market - Live News
Alivus Life Sciences standalone net profit rises 15.32% in the December 2024 quarter
143 days ago

Alivus Life Sciences standalone net profit rises 15.32% in the December 2024 quarter

23 - Jan - 2025 12:00 | 143 days ago

Net profit of Alivus Life Sciences rose 15.32% to Rs 136.96 crore in the quarter ended December 2024 as against Rs 118.77 crore during the previous quarter ended December 2023. Sales rose 12.05% to Rs 641.84 crore in the quarter ended December 2024 as against Rs 572.80 crore during the previous quarter ended December 2023.
Particulars Quarter Ended
Dec. 2024 Dec. 2023 % Var.
Sales 641.84 572.80 12
OPM % 29.65 30.13 -
PBDT 200.31 173.87 15
PBT 185.15 160.69 15
NP 136.96 118.77 15
Powered by Capital Market - Live News
Alivus Life jumps after Q3 PAT climbs 15% YoY to Rs 137 cr
143 days ago

Alivus Life jumps after Q3 PAT climbs 15% YoY to Rs 137 cr

23 - Jan - 2025 12:00 | 143 days ago

Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25.
For Q3FY25, EBITDA was at Rs 200.8 crore, a growth of 15.2% YoY. EBITDA margin stood at 31.3%, up 90 bps YoY.
On segmental front, the revenue from Generic API grew by 16.9% YoY to Rs 596.6 crore in Q3 FY25 while revenue from CDMO declined 14.29% YoY to Rs 30 crore in Q3 FY25.
Yasir Rawjee, MD & CEO, Alivus Life Sciences, said, “The start of the new year marks a notable shift for us as we transition to Alivus Life Sciences. I am pleased to report that our Q3 performance reflects this renewed energy, with growth across both GPL and Non-GPL segments. Geographically, regions like India, Europe, ROW and Japan contributed to the growth.
Alivus Life Sciences (Formerly Glenmark Life Sciences) is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. It has a diversified portfolio of 161 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW).
Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

MF shareholding in Glenmark Life Sciences Ltd has increased by 11.39% since past 3 Months
FII shareholding in Glenmark Life Sciences Ltd has increased by 31.08% since past 1 Year
MF shareholding in Glenmark Life Sciences Ltd has increased by 287.07% since past 1 Year
Promoter shareholding in Glenmark Life Sciences Ltd has decreased by -9.48% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Dec. 2024	Dec. 2023	% Var.
Sales	641.84	572.80	12
OPM %	29.65	30.13	-
PBDT	200.31	173.87	15
PBT	185.15	160.69	15
NP	136.96	118.77	15

General Notifications

My Notifications

Research Notifications

Alivus Life Sciences Ltd Share Price – NSE / BSE Pharmaceuticals, Small Cap

1,014.20 -14.60 (-1.42%)

News & Announcements

Price vs Volume

Stock Trivia

Alivus Life Sciences Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

1,014.20

-14.60 (-1.42%)